VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CLOVClover Health Investments, Corp.
$5.41$2.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCLOVCash Flow

Clover Health Investments, Corp. (CLOV) Cash Flow Statement

8Y historyFree accessUpdated daily

Free cash flow reached a positive $107.0M in 2026Q1, marking a significant turnaround from the $257.8M burn observed in 2023Q4.

CLOV Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations57.25M-66.93M34.84M-115.87M-203.93M-282.33M-118.5M-159.88M-153.28M
Operating CF Margin %--3.48%2.54%-9.19%-18.6%-19.18%-17.61%-34.59%-54.54%
Operating CF Growth %619.11%-292.09%130.07%43.18%27.77%-138.25%25.88%-4.3%-
Net Income-56.94M-85.55M-43.01M-213.36M-339.57M-587.76M-136.39M-363.74M-201.93M
Depreciation & Amortization1.22M1.69M1.33M2.51M1.19M1.25M0551K487K
Stock-Based Compensation77.22M103.66M114.33M140.93M164.31M163.72M03.3M3.68M
Deferred Taxes00000-66.09M000
Other Non-Cash Items18.51M-2.53M-50.66M9.48M-27.49M13.88M42.35M167.7M9.51M
Working Capital Changes17.24M-84.2M12.86M-55.43M-2.36M192.67M-24.46M32.31M34.97M
Change in Receivables-3.81M0-6.55M0-8.03M-9.39M060.76M-11.49M
Change in Inventory0--------
Change in Payables5.66M0-2.62M4.74M7.63M5.31M06.3M0
Cash from Investing-9.92M4.08M565K140.01M95.13M-435.45M141.31M-181.91M97.53M
Capital Expenditures-2.71M-2.04M-1.56M-584K-4.47M-723K-693K-23K-1.48M
CapEx % of Revenue0.12%0.11%0.11%0.05%0.41%0.05%0.1%0.01%0.53%
Acquisitions0--------
Investments---------
Other Investing00000-434.72M0099M
Cash from Financing-29.51M-53.38M-17.36M-33.86M-4.96M925.39M1.94M333.98M74.59M
Debt Issued (Net)0--------
Equity Issued (Net)-29.51M-53.38M-17.36M-5.07M-4.96M289.77M1.75M601K0
Dividends Paid000000000
Share Repurchases-31.14M-55.2M-18.26M-6.22M-6.36M-147K000
Other Financing000-28.79M0666.55M-957K-363K44.83M
Net Change in Cash17.83M-116.24M18.05M-9.72M-113.75M207.62M92.35M-7.8M18.83M
Free Cash Flow54.54M-68.98M33.29M-116.45M-208.39M-283.05M-119.19M-159.9M-154.76M
FCF Margin %2.47%-3.58%2.43%-9.24%-19%-19.23%-17.71%-34.59%-55.07%
FCF Growth %728.44%-307.21%128.59%44.12%26.38%-137.48%25.46%-3.32%-
FCF per Share0.10-0.130.07-0.24-0.44-0.60-0.29-0.40-3.68
FCF Conversion (FCF/Net Income)-0.96x0.78x-0.81x0.54x0.60x0.48x0.87x0.44x0.76x
Interest Paid00000006.26M0
Taxes Paid000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Regulatory reimbursement volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Conversion

According to recent financial disclosures, Clover Health's operating cash flow reached $107.9M in 2026Q1, significantly outpacing net income of $27.3M, which suggests that the company's reported earnings are currently benefiting from substantial non-cash adjustments and favorable working capital movements rather than pure operational cash generation.

The wide variance between net income and operating cash flow warrants caution, as it indicates that accounting profits may not yet be fully supported by cash inflows. Investors should monitor whether this conversion gap persists as the company matures, as reliance on working capital swings to bolster cash flow is rarely sustainable over the long term.

Free Cash Flow Inflection Point

As reported in quarterly filings, Clover Health's free cash flow trajectory has shifted from a $257.8M burn in 2023Q4 to a positive $107.0M in 2026Q1, reflecting a fundamental pivot toward fiscal discipline and the successful shedding of lower-margin, cash-intensive business segments within the insurance portfolio.

This transition to positive free cash flow appears to be a direct result of management's strategic focus on core Medicare Advantage profitability. While the improvement is notable, the sustainability of this trend remains contingent on the company's ability to maintain medical care ratios without the support of non-insurance revenue streams.

Working Capital Volatility Impacts Liquidity

Based on the provided cash flow statements, working capital changes have been a primary driver of quarterly cash fluctuations, most notably contributing a $68.1M inflow in 2026Q1 compared to a $211.8M outflow in 2023Q4, highlighting the company's sensitivity to timing differences in CMS premium settlements and claim payments.

The high volatility in working capital suggests that Clover's cash position is susceptible to the timing of government reimbursements and the settlement of medical claims. This dependency implies that short-term liquidity may appear stronger or weaker than the underlying operational performance would otherwise suggest.

SBC Masking True Cash Burn

As indicated by historical data, Clover Health consistently records stock-based compensation expenses exceeding $25M per quarter, which effectively obscures the true cash cost of operations and suggests that the company's path to profitability is partially subsidized by significant dilution of existing shareholders' equity interests.

While stock-based compensation is a non-cash expense, it represents a real economic cost that should be factored into any assessment of the company's long-term cash generation capabilities. The reliance on equity-based incentives may indicate that management is attempting to preserve cash while still attracting the talent necessary to scale the Clover Assistant platform.

CLOV — Frequently Asked Questions

Quick answers to the most common questions about buying CLOV stock.

How much cash does Clover Health Investments, Corp. (CLOV) generate from operations?

Clover Health Investments, Corp. (CLOV) generated $-66.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Clover Health Investments, Corp.'s free cash flow?

Clover Health Investments, Corp. (CLOV) reported negative free cash flow of $69.0M in 2025, indicating capital requirements exceeded cash from operations.

What is Clover Health Investments, Corp.'s capital expenditure (CapEx)?

Clover Health Investments, Corp. (CLOV) spent $2.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Clover Health Investments, Corp. distribute cash to shareholders?

In 2025, Clover Health Investments, Corp. (CLOV) spent $55.2M on share repurchases. This shows the company's commitment to returning capital to its equity investors.